Endoscopic Assessment and Prediction of Microbiome-modifying Interventions
NCT ID: NCT03218579
Last Updated: 2017-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
45 participants
INTERVENTIONAL
2013-02-01
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Outcomes of probiotic treatment versus bacteriotherapy will be compared.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms
NCT05845073
The Effect of Probiotics on GI Symptoms
NCT03959722
Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile
NCT02127814
The Effect of Probiotic Intervention on Intestinal Permeability
NCT03027583
Probiotics: is it Really That Good? Cost-Effectiveness of Treating the in-Patient
NCT00506181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Since the digestive mocus enables the connection between the host and the bacteria that live within it, the investigators would like to characterize the microbiome in the different areas along the digestive system - before antibiotic treatment and after rehabilitation by probiotic treatment versus bacteriotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No intervention
No intervention after antibiotic treatment.
No interventions assigned to this group
Probiotic microbiome rehabilitation
Probiotic treatment after antibiotic treatment.
Probiotic treatment
4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Bacteriotherapy microbiome rehabilitation
Bacteriotherapy after antibiotic treatment.
Bacteriotherapy
Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic treatment
4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Bacteriotherapy
Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18 years and up
* Gender: women and men
Exclusion Criteria
* Age under 18 years
* antibiotic treatment 3 months prior to enrollment
* Viral Hepatitis
* HIV positive
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Weizmann Institute of Science
OTHER
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zamir Halpern, MD
Role: PRINCIPAL_INVESTIGATOR
Tel-Aviv Sourasky Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastroentherology
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TASMC-12-ZH-658-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.